Comparison of Mortality and Therapy in Community Acquired Pneumonia

Authors

Gina Maki, Henry Ford Health SystemFollow
Daniela Moreno, Henry Ford Health SystemFollow
Anthony Harris, University of MarylandFollow
Steven Lawrence, Washington UniversityFollow
Andrew Masica, Baylor Scott & White Health, DallasFollow
Lois Lamerato, Henry Ford Health SystemFollow
Marcus J. Zervos, Henry Ford Hospital, Detroit, MIFollow

Funder

This collaborative research study was sponsored by Pfizer.

Abstract

Background: Community associated pneumonia (CAP) is one the most common causes of hospital admissions, exceeding more than one million per year in the United States, contributing to 3.4% of inpatient mortality. Our objective was to compare 30-day mortality using therapies recommended for treatment of CAP.

Methods: A multicenter retrospective analysis from four different hospitals was assessed from 2008 to 2013. The data was obtained from electronic medical records which included more than 70,000 patients. CAP patients were identified using discharge diagnostic codes during the years 2008-2013, as well as receiving therapy with ceftriaxone and azithromycin or a respiratory fluoroquinolone. Demographic data, antibiotic therapy, and Charlson comorbidity score was obtained to compare the study groups.

Results: A total of 21,800 patients met the inclusion criteria for CAP. 1,740 patients were excluded as they received both beta-lactams and fluoroquinolones. The study included 20,600 patients. 11,201 patients (55.84%) received ceftriaxone with azithromycin, and 8,859 (44.16%) received fluoroquinolone therapy. The mortality rate for patients who received fluoroquinolone therapy was lower compared to the patients who received ceftriaxone plus azithromycin (3.56% vs 6.71%, p-value <0.001).

Conclusion: Our study showed statistically significant lower 30-day mortality using fluoroquinolone therapy compared to ceftriaxone plus azithromycin for treatment of CAP. Prospective blinded randomized control trials would be needed to support this evidence.

DOI

10.18297/jri/vol2/iss2/5/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Maki, Gina; Moreno, Daniela; Harris, Anthony; Lawrence, Steven; Masica, Andrew; Lamerato, Lois; and Zervos, Marcus J. (2018) "Comparison of Mortality and Therapy in Community Acquired Pneumonia," The University of Louisville Journal of Respiratory Infections: Vol. 2 : Iss. 2 , Article 5.
DOI: https://doi.org/10.18297/jri/vol2/iss2/5/
Available at: https://ir.library.louisville.edu/jri/vol2/iss2/5